



phoresis and paper chromatography was found to be more than 99.8%. The enzyme activity and immunological behavior observed by immunoelectrophoresis of  $^{131}\text{I}$ -EWL were identical with those of the starting material.

Male rats (230–290 g) of Wistar strain were given 1 mM KI aqueous solution, fasted for 24 hr and then the thoracic duct was cannulated as described previously.<sup>1c)</sup> Following the




Fig. 1. Serum and Lymph Levels of Immunoprecipitable  $^{131}\text{I}$  ( $\blacktriangle$ ,  $\bullet$ ) or TCA Precipitable  $^{131}\text{I}$  ( $\triangle$ ,  $\circ$ ) following Intraintestinal Administration of  $^{131}\text{I}$ -EWL (2 mg/kg)

Data are expressed as mean ( $n=4$ ).

Fig. 1 shows the time course of TCA precipitable and immunoprecipitable  $^{131}\text{I}$  as EWL eq  $\mu\text{g}$  per ml of serum or lymph after intraintraintestinal administration of  $^{131}\text{I}$ -EWL 2 mg/kg.

As shown in Fig. 1, the concentration of immunoprecipitable  $^{131}\text{I}$  at each time was in good accordance with that of TCA precipitable  $^{131}\text{I}$ . The maximum level observed at 30 min in lymph,  $0.529 \pm 0.106 \mu\text{g/ml}$ , was approximately 5 times higher than that in serum.

After intravenous administration of  $^{131}\text{I}$ -EWL, the serum concentration of immunoprecipitable  $^{131}\text{I}$  was declined biexponentially. Then the serum levels ( $Cp$ ) were fitted to the equation,  $Cp = A \exp(-\alpha t) + B \exp(-\beta t)$ , by the least-square method. The parameters of  $A$ ,  $B$ ,  $\alpha$  and  $\beta$  were  $6.57 \pm 0.32$ ,  $1.10 \pm 0.22 \mu\text{g/ml}$ ,  $5.225 \pm 0.138$  and  $0.236 \pm 0.017 \text{ hr}^{-1}$ , respectively. The transfer rate of immunoprecipitable  $^{131}\text{I}$  to lymph after intravenous injection of  $^{131}\text{I}$ -EWL was only 1% of the dose during the first 6 hr. This finding demonstrates that the transfer of  $^{131}\text{I}$ -EWL from blood to lymph is negligible. The amount of immunoprecipitable  $^{131}\text{I}$  absorbed *via* portal vein was calculated with the parameters according to the method of Loo and Riegelman.<sup>5)</sup> The amounts of absorption *via* lymphatics and the portal vein, and the percentages of absorption *via* lymphatics to the total immunoprecipitable  $^{131}\text{I}$  absorbed are shown in Table I.

3) K. Katayama and T. Fujita, *Biochim. Biophys. Acta*, **288**, 172 (1972).

4) G. Gorin, S.F. Wang and L. Papapavlou, *Anal. Biochem.*, **39**, 113 (1971).

5) J.C.K. Loo and S. Riegelman, *J. Pharm. Sci.*, **57**, 918 (1968).

TABLE I. Absorption of Immunoprecipitable  $^{131}\text{I}$  *via* Portal Vein and Lymphatics after Intraintestinal Administration of  $^{131}\text{I}$ -EWL 2 mg/kg in Rats

Absorption	EWL eq $\mu\text{g}$	% of dose
Amount <i>via</i> portal vein (A)	$10.61 \pm 2.40$	$1.99 \pm 0.41$
Amount <i>via</i> lymphatics (B)	$0.37 \pm 0.18$	$0.07 \pm 0.04$
Amount <i>via</i> both routes (A+B)	$10.98 \pm 2.45$	$2.06 \pm 0.43$
Percentage of lymphatics [ $100 \times (\text{B})/(\text{A} + \text{B})$ ]		$3.24 \pm 1.69$

Each value is represented as mean with S.E. of 4 experiments.

Table I indicates that the main route in intestinal absorption of  $^{131}\text{I}$ -EWL is the portal vein, not lymphatics. This result seems to be in accordance with the results of heparin<sup>1d)</sup> and insulin.<sup>1e)</sup> However, as compared with the result that 36% of the total amount of elastase absorbed was *via* lymphatics,<sup>1e)</sup> the percentage of lymphatics absorption of  $^{131}\text{I}$ -EWL is extremely small. Thus, further studies on the relationship between the physicochemical properties of macromolecules and the absorption rate *via* lymphatics will be necessary. In addition, whether or not the immunoprecipitable and protein-bound  $^{131}\text{I}$  in serum and lymph originates from intact  $^{131}\text{I}$ -EWL administered remains to be investigated.

**Acknowledgement** The authors thank Dr. S. Ohtake for his valuable advice, Mr. Y. Hidaka for the gift of purified hen egg white lysozyme and also Mr. T. Naito for his support of this research.

Department of Drug Metabolism,  
Section of Experimental  
Therapeutics Research,  
Research & Development Division,  
Eisai Co., Ltd.,  
4-6-10 Koishikawa Bunkyo-ku Tokyo

TERUAKI YUZURIHA  
KOUICHI KATAYAMA  
TAKESHI FUJITA

Received August 31, 1973

[Chem. Pharm. Bull.]  
21(12)2809-2811(1973)

UDC 547.677.2.04 : 541.14

### Wave Length Dependent Photolysis of Phenanthrene Oxide

Though the chemistry of monocyclic arene oxides has been investigated,<sup>1)</sup> studies on polycyclic arene oxides are very poor.<sup>2)</sup> The evidence, however, is growing that arene oxides are the active carcinogens formed from polycyclic aromatic hydrocarbons.<sup>3)</sup> The stereochemistry of polycyclic arene oxides is dreamy: the epoxide ring is nearly perpendicular to the aromatic ring(s) from investigation by a Dreiding Model. This may cause an extensive conjugation between the pi-bonds and the C-O sigma-bonds.<sup>4)</sup> These situations prompted us to investigate the chemical behaviour of compounds of this kind. In this communication

- 1) J.W. Daly, D.M. Jerina and B. Witkop, *Experientia*, **15**, 1129 (1972).
- 2) D.M. Jerina and D.R. Boyd, *Tetrahedron letters*, **1970**, 457; M.S. Newman and S. Blum, *J. Am. Chem. Soc.*, **86**, 5559 (1964).
- 3) for example, J.K. Selkirk, H. Huberman and C. Heiderberger, *Biochem. Biophys. Res. Commun.*, **43**, 1010 (1971).
- 4) T.G. Traylor, W. Hanstein, H.J. Berwin, N.A. Clinton and R.S. Brown, *J. Am. Chem. Soc.*, **93**, 5715 (1971).